 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 1 | 1 | 2 | | 1983 | 1 | 0 | 1 | | 1986 | 3 | 2 | 5 | | 1987 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 3 | 1 | 4 | | 1991 | 0 | 1 | 1 | | 1992 | 2 | 0 | 2 | | 1994 | 1 | 2 | 3 | | 1995 | 2 | 5 | 7 | | 1997 | 4 | 0 | 4 | | 1998 | 9 | 1 | 10 | | 1999 | 2 | 1 | 3 | | 2000 | 3 | 2 | 5 | | 2001 | 7 | 3 | 10 | | 2002 | 4 | 3 | 7 | | 2003 | 9 | 2 | 11 | | 2004 | 12 | 3 | 15 | | 2005 | 7 | 2 | 9 | | 2006 | 7 | 4 | 11 | | 2007 | 12 | 3 | 15 | | 2008 | 8 | 1 | 9 | | 2009 | 10 | 5 | 15 | | 2010 | 8 | 4 | 12 | | 2011 | 5 | 3 | 8 | | 2012 | 9 | 2 | 11 | | 2013 | 14 | 1 | 15 | | 2014 | 10 | 2 | 12 | | 2015 | 9 | 1 | 10 | | 2016 | 9 | 9 | 18 | | 2017 | 4 | 3 | 7 | | 2018 | 5 | 4 | 9 | | 2019 | 6 | 1 | 7 | | 2020 | 5 | 1 | 6 | | 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.
-
Nunna RS, Khalid SI, Patel S, Sethi A, Behbahani M, Mehta AI, Adogwa O, Byrne RW. Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. World Neurosurg. 2021 05; 149:e1026-e1037.
-
Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
-
Feng L, Pomel S, Latre de Late P, Taravaud A, Loiseau PM, Maes L, Cho-Ngwa F, Bulman CA, Fischer C, Sakanari JA, Ziniel PD, Williams DL, Davioud-Charvet E. Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections. Molecules. 2020 Nov 01; 25(21).
-
Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, Rodríguez ML, López A, Tamayo-Torres E, Chuliá-Peris L, García-Cañaveras JC, Soucheray M, Dalheim AV, Salom JB, Qiu W, Kaja S, Fernández-Coronado JA, Alandes S, Alcácer J, Al-Shahrour F, Borgia JA, Juan O, Nishimura MI, Lahoz A, Carretero J, Shimamura T. Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020 10 01; 80(19):4224-4232.
-
Kalra D, Tesfazghi M. Falsely Elevated Digoxin Levels in Patients on Enzalutamide. Circ Heart Fail. 2020 07; 13(7):e007008.
-
Zhang XZ, Luo DX, Bai XH, Ding HH, Liu M, Deng J, Mai JW, Yang YL, Zhang SB, Ruan XC, Zhang XQ, Xin WJ, Xu T. Upregulation of TRPC6 Mediated by PAX6 Hypomethylation Is Involved in the Mechanical Allodynia Induced by Chemotherapeutics in Dorsal Root Ganglion. Int J Neuropsychopharmacol. 2020 04 23; 23(4):257-267.
-
Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
-
Brown SA, Okwuosa TM, Barac A, Volgman AS. The Role of Angiotensin-Converting Enzyme Inhibitors and ß-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients. J Am Heart Assoc. 2020 01 21; 9(2):e015327.
-
Tierney JF, Chivukula SV, Poirier J, Pappas SG, Schadde E, Hertl M, Kebebew E, Keutgen X. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? J Clin Endocrinol Metab. 2019 12 01; 104(12):5948-5956.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|